. Author manuscript; available in PMC: 2024 Aug 1.

Published in final edited form as: Curr Treat Options Oncol. 2023 Jun 10;24(8):948–964. doi: 10.1007/s11864-023-01111-1

Table 2.

Ongoing Trials in Adult T-cell Leukemia/Lymphoma (ATL).

Trial	Regimen	Population	Design	Notes
NCT04301076	lenalidomide + EPOCH	untreated acute, lymphoma, or poor-risk chronic subtype ATL	phase I	NCI sponsored, estimated completion 2023
NCT03264131	BV-CHEP	untreated acute, lymphoma, or poor-risk chronic subtype ATL	pilot/phase I	interim results,³³ showing 75% ORR in 8 patients
NCT04502446	CTX130	R/R T-cell lymphoma, including ATL	phase I	anti-CD70 allogeneic CRISPR-Cas9-engineered T cells, interim results⁹¹
recombinant human IL-15 (rhIL-15) combinations (NCT02689453, NCT04185220)	rhIL-15 + mogamulizumab or alemtuzumab	R/R T-cell lymphoma, including ATL	phase I	NCI sponsored
NCT04848046	NK cell therapy + mogamulizumab	R/R ATL or CTCL	phase I	IL-21 expanded, off-the-shelf NK cell therapy
NCT02737046	belinostat + ZDV +/− IFN	aggressive ATL with persistent circulating disease after prior chemotherapy or ZDV/IFN	phase II	interim results of 6 patients reported, potential to achieve complete molecular CR⁹²
NCT04703192 (VALENTINE-PTCL01)	valemetostat	R/R T-cell lymphoma, including ATL	phase II	enrollment complete, registration study
JCOG1111C	IFN/AZT versus watchful waiting	indolent ATL (symptomatic smoldering or chronic w/o unfavorable features)	open-label, randomized phase III	led by Japanese Clinical Oncology Group (JCOG)

BV, brentuximab vedotin; CR, complete response; CTCL, cutaneous T-cell lymphoma; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; IFN, interferon; NCI, National Cancer Institute; NK, natural killer; ORR, objective response rate; R/R, relapsed/refractory; ZDV, zidovudine.